Dongwha Pharm Launches Acne Treatment 'Sebitavigel'

[Asia Economy Reporter Lee Gwan-joo] Dongwha Pharm announced on the 27th that it has launched 'Sebitavigel,' the first acne treatment in Korea containing nicotinic acid amide (active vitamin B3).

Sebitavigel is a treatment effective for mild to moderate inflammatory acne. Acne occurs due to excessive sebum secretion caused by hormonal imbalance and external factors. The main ingredient of Sebitavigel, nicotinic acid amide, improves acne symptoms with excellent anti-inflammatory effects and helps reduce redness.

Additionally, Dongwha Pharm re-released Fucidin Gel by adding tea tree oil, which has skin-soothing effects, and increasing the dosage by 50% compared to the previous version. Fucidin Gel can be used for acne, wounds, and folliculitis. Dongwha Pharm plans to target the acne treatment market with Sebitavigel and the newly renewed Fucidin Gel.

A Dongwha Pharm official stated, “In the early stages of acne, we recommend consistently using Sebitavigel to reduce inflammation, and using Fucidin Gel to manage wounds and secondary infections caused by acne extraction, effectively managing skin troubles.”

This content was produced with the assistance of AI translation services.